Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. [artículo
Por: Lagarde Sebastián, María de [Medicina Interna]
| Pulido Ortega, Federico [Unidad VIH] | Rubio García, Rafael [Unidad de VIH].
Colaborador(es): Servicio de Medicina Interna.
Editor: PloS one, 2013Descripción: 8(7):e69493.Recursos en línea: Acceso libre Resumen: BACKGROUND: In patients who remain virologically suppressed in plasma with triple-drug ART a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is unknown if protease inhibitor monotherapy is associated to a higher rate of neurocognitive impairment.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC12514 (Navegar estantería) | Disponible |
Formato Vancouver:
Pérez-Valero I, González-Baeza A, Estébanez M, Montes-Ramírez ML, Bayón C, Pulido F et al. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One.
2013 Jul 25;8(7):e69493.
PMID: 23936029
Contiene 32 referencias
BACKGROUND: In patients who remain virologically suppressed in plasma with triple-drug ART a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is unknown if protease inhibitor monotherapy is associated to a higher rate of neurocognitive impairment.
No hay comentarios para este ejemplar.